Side-by-side comparison of AI visibility scores, market position, and capabilities
Parent Unilever 2024: Turnover €60.8B (+1.9%) | Personal Care: €13.6B (+5.2% organic sales growth) | Dove: ~40% of Personal Care, high-single digit growth | Key launches: whole-body deodorant, serum shower collection | Op Profit +12.6% to €11.2B, margin +170bp to 18.4% | H1-Q3 2025: Beauty/Wellbeing +4.1%, Personal Care +5.1% | 2025 target: 3-5% organic sales growth
Dove is a global personal care brand under Unilever offering body wash, beauty bars, deodorants, hair care, and skincare products formulated with moisturizing ingredients and positioned around real beauty and self-esteem. The company serves women, men, and families seeking gentle, nourishing personal care products that respect skin health. Dove differentiates itself through its Real Beauty campaign challenging traditional beauty standards, dermatologist-recommended formulations with 1/4 moisturizing cream, inclusive marketing featuring diverse body types and ages, and commitment to building confidence through the Dove Self-Esteem Project.
Richmond VA tobacco and nicotine (NYSE: MO) ~$9.7B net revenue FY2024; Marlboro 40%+ US cigarette share, on! oral pouch competing with Zyn, 50%+ operating margins, ABI stake, competing with Reynolds/BAT.
Altria Group, Inc. is a Richmond, Virginia-based tobacco and nicotine company — publicly traded on the New York Stock Exchange (NYSE: MO) as an S&P 500 Consumer Staples component — manufacturing and selling cigarettes (Marlboro — the best-selling cigarette brand in the United States), smokeless tobacco (Copenhagen, Skoal, Red Seal, Husky chewing tobacco/moist snuff brands), oral nicotine pouches (on! brand), and maintaining a 10.7% ownership stake in Anheuser-Busch InBev (SABMiller acquisition consideration shares) and a 35% stake in JUUL Labs (vaping — original $12.8B investment written down to minimal value following JUUL's regulatory and litigation difficulties) through approximately 5,500 employees. In fiscal year 2024, Altria reported revenues of approximately $20.6 billion (net revenues after excise taxes approximately $9.7 billion), with the cigarette segment (Marlboro generating 40%+ US cigarette market share) contributing the majority of operating income at 50%+ adjusted operating margins — the highest margins in the consumer staples sector reflecting cigarettes' inelastic demand and regulated market structure. CEO Billy Gifford has pivoted Altria's strategy from cigarettes toward smoke-free nicotine products: the on! oral nicotine pouch (acquired full ownership of Helix Innovations in 2023, rebranding as on! to compete with Swedish Match Zyn, the dominant US oral nicotine pouch brand) represents Altria's primary nicotine product diversification vehicle as cigarette volume declines 7-8% annually through consumer quit rates and secular health awareness trends.
Monitor how your brand performs across ChatGPT, Gemini, Perplexity, Claude, and Grok daily.